12 Month Price Forecast For NVAX
Distance to NVAX Price Forecasts
NVAX Price Momentum
🤔 Considering Novavax (NVAX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 11:21 AM UTC
NVAX Analyst Ratings & Price Targets
Based on our analysis of 13 Wall Street analysts, NVAX has a consensus that is neutral. The median price target is $15.50, with forecasts ranging from $9.00 to $25.00. Currently, there are 3 Buy ratings, 2 Hold ratings, and 1 Sell ratings.
With NVAX currently trading at $8.83, the median price forecast suggests a 75.5% upside. The most optimistic forecast comes from Roger Song at Jefferies, projecting a 183.1% upside, while Eric Joseph at JP Morgan provides the most conservative target, suggesting a 1.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVAX Analyst Consensus
NVAX Price Target Range
Latest NVAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $19.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $19.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $19.00 |
| Oct 16, 2024 | Jefferies | Roger Song | Buy | Maintains | $25.00 |
| Oct 10, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $26.00 |
| Oct 2, 2024 | Jefferies | Roger Song | Buy | Maintains | $31.00 |
| Aug 12, 2024 | JP Morgan | Eric Joseph | Underweight | Maintains | $9.00 |
| Aug 12, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $23.00 |
| Aug 2, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $25.00 |
| Jul 30, 2024 | JP Morgan | Eric Joseph | Underweight | Downgrade | $8.00 |
| Jun 14, 2024 | B of A Securities | Alec Stranahan | Neutral | Maintains | $18.00 |
| May 23, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $29.00 |
| May 13, 2024 | TD Cowen | Brendan Smith | Hold | Maintains | $10.00 |
| May 13, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $19.00 |
| May 10, 2024 | B of A Securities | Alec Stranahan | Neutral | Upgrade | $12.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $19.00 |
| Feb 23, 2024 | B. Riley Securities | Buy | Maintains | $0.00 | |
| Aug 10, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $35.00 |
| Aug 9, 2023 | B. Riley Securities | Mayank Mamtani | Buy | Upgrade | $15.00 |
| May 10, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $35.00 |
Stocks Similar to Novavax Inc
The following stocks are similar to Novavax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Novavax Inc (NVAX) Financial Data
Novavax Inc has a market capitalization of $1.41B with a P/E ratio of -1.6x. The company generates $885.19M in trailing twelve-month revenue with a -32.2% profit margin.
Revenue growth is -54.8% quarter-over-quarter, while maintaining an operating margin of -153.6% and return on equity of +76.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Novavax Inc (NVAX) Company Overview
About Novavax Inc
Develops vaccines for infectious diseases.
The company’s business model revolves around the research, development, and commercialization of vaccines, particularly targeting serious infectious diseases such as COVID-19 and influenza. It generates revenue through the sale of its vaccines, including its COVID-19 vaccine NVX-CoV2373, which is marketed under various brand names and is offered as both a primary series and booster shots.
Novavax is leveraging innovative technologies such as recombinant protein and nanoparticle technology, alongside its proprietary Matrix-M adjuvant, to enhance immune responses. Founded in 1987 and based in Gaithersburg, Maryland, the company is focused on urgent health challenges and is also developing a malaria vaccine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,543
CEO
Mr. John Charles Jacobs M.B.A.
Country
United States
IPO Year
1995
Website
www.novavax.comNovavax Inc (NVAX) Latest News & Analysis
Novavax (NVAX) closed at $8.55, reflecting a 0.53% increase from the previous trading day.
Novavax's slight increase in share price indicates potential investor confidence or positive market sentiment, which could impact future trading and investment decisions.
Novavax (NVAX) saw a rise in share price with above-average trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
NVAX's share price surge on high volume indicates short-term interest, but stagnant earnings estimate revisions may signal potential weakness ahead, affecting long-term investor confidence.
Zacks.com users are increasingly focused on Novavax (NVAX), indicating heightened interest that may warrant further investigation into the stock's potential.
Increased attention on Novavax (NVAX) signals potential volatility or interest, which may impact stock performance and investment decisions.
Here's why vaccine stocks are surging in 2025
15 days agoMajor vaccine stocks experienced a significant boost in early 2025 after years of decline related to reduced reporting and awareness of the COVID-19 pandemic.
Vaccine stocks rising in early 2025 signals renewed investor interest, potentially indicating a shift in market dynamics and highlighting the ongoing relevance of public health issues.
The first U.S. bird-flu death has increased investor interest in companies developing experimental H5N1 vaccines.
The bird-flu fatality can drive demand for H5N1 vaccines, potentially boosting revenues and stock prices for vaccine manufacturers involved in development.
Moderna stock rose following a CDC report of a two-week increase in positive COVID tests, also boosting shares of BioNTech and Novavax.
The CDC's report of a Covid surge can boost demand for vaccines, potentially increasing revenues for Moderna and similar companies, impacting their stock performance positively.
Frequently Asked Questions About NVAX Stock
What is Novavax Inc's (NVAX) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Novavax Inc (NVAX) has a median price target of $15.50. The highest price target is $25.00 and the lowest is $9.00.
Is NVAX stock a good investment in 2025?
According to current analyst ratings, NVAX has 3 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $8.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NVAX stock?
Wall Street analysts predict NVAX stock could reach $15.50 in the next 12 months. This represents a 75.5% increase from the current price of $8.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Novavax Inc's business model?
The company’s business model revolves around the research, development, and commercialization of vaccines, particularly targeting serious infectious diseases such as COVID-19 and influenza. It generates revenue through the sale of its vaccines, including its COVID-19 vaccine NVX-CoV2373, which is marketed under various brand names and is offered as both a primary series and booster shots.
What is the highest forecasted price for NVAX Novavax Inc?
The highest price target for NVAX is $25.00 from Roger Song at Jefferies, which represents a 183.1% increase from the current price of $8.83.
What is the lowest forecasted price for NVAX Novavax Inc?
The lowest price target for NVAX is $9.00 from Eric Joseph at JP Morgan, which represents a 1.9% increase from the current price of $8.83.
What is the overall NVAX consensus from analysts for Novavax Inc?
The overall analyst consensus for NVAX is neutral. Out of 13 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $15.50.
How accurate are NVAX stock price projections?
Stock price projections, including those for Novavax Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
